Volume 4, Issue 1 (2-2020)                   GMJ Medicine 2020, 4(1): 185-195 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sharifi S, Saberi K, Rahmanian M, Bakhshandeh A R. Effect of Perioperative Administration of Dexmedetomidine in Cardiac Surgeries: A Double-blind, Placebo-controlled Trial. GMJ Medicine. 2020; 4 (1) :185-195
URL: http://gmjpress.de/article-1-67-en.html
1- PhD student of Medical Education, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of medical sciences, Tehran, Iran
2- Imam Khomeini Medical and Research Centre, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (127 Views)
Background and purpose: Despite many developments in the health care of cardiac surgery patients, yet 5%–30% of them may become challenged due to renal dysfunction, delirium, and arrhythmia. Eliminating or reducing these unwanted outcomes is likely to improve the prognosis of them. Several studies suggested that dexmedetomidine (DEX), a highly selective short-acting α-2 adrenergic agonist predominantly used for anti-delirium and sedative characteristics, may be useful for reducing the adverse effect of cardiac surgeries. The purpose of the current study was to investigate the outcome of the administration of DEX in patients undergoing cardiac surgeries. 
Method: We included the data from patents who underwent coronary artery bypass grafting (CABG) without a valve, CABG with valve surgery, and valve-only surgery from August 2018 to November 2018. A total of 51 patients were eligible for our study after extraction. For the DEX group, the infusion of DEX was started 10 min before anesthesia induction in a 0.2–0.6 µg/Kg/h rate. And the same amount of normal saline (0.9%) was infused for the control group. The infusion was continued post-operatively until extubation (maximum for 24 h). The patients were compared primarily for Acute Kidney Injury (AKI), delirium, new-onset atrial fibrillation (AF) rhythm.
Results: We had a total of 51 patients among which 33 (64.70%) received DEX, and 18 (35.29%) received a placebo. There was no significant difference between groups for demographic data. One patient (16.7%) from the DEX group and five patients (83.3%) from the control group revealed an AF rhythm after surgery (p=0.009). No patient faced delirium. Seven patients seemed to be AKI, of which five (71.4%) were in the DEX group and two (28.6%) were in the control group (p>0.05).
Conclusion: There might be a meaningful reduction of new-onset AF rhythm in adult patients who use DEX after cardiac surgeries.
     
Type of Study: Original Article | Subject: Clinical Medicine
Received: 2019/11/7 | Accepted: 2020/01/25 | Published: 2020/02/10

Add your comments about this article : Your username or Email:
CAPTCHA

© 2020 All Rights Reserved | GMJ Medicine